Bristol-Myers Squibb has signed another deal to build its capabilities in antibody-drug conjugates for cancer, paying $100 million upfront to take control of an Orum Therapeutics candidate with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback